

PHARMACEUTICAL 2023



ALX ONCOLOGY HOLDINGS INC Rank 108 of 446











ALX ONCOLOGY HOLDINGS INC Rank 108 of 446



The relative strengths and weaknesses of ALX ONCOLOGY HOLDINGS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALX ONCOLOGY HOLDINGS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of ALX ONCOLOGY HOLDINGS INC is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 145% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	270,969
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,325
Liabilities, Non-Current	14,700
Other Assets	31,631
Other Compr. Net Income	-845
Other Expenses	64
Other Liabilities	0
Other Net Income	4,018
Other Revenues	0
Property and Equipment	3,889
Research and Development	98,400
Selling, General and Administrative Expense	29,036

Output Variable	Value in 1000 USD
Assets	306,489
Liabilities	43,025
Expenses	127,500
Revenues	0
Stockholders Equity	263,464
Net Income	-123,482
Comprehensive Net Income	-123,904
Economic Capital Ratio	188%

